Sign in

You're signed outSign in or to get full access.

Anna Lee

Research Analyst at Truist Financial Corp.

There is no verifiable public information available confirming the existence of Anna Lee as an analyst at Truist, nor any details regarding her job title, specific company coverage, performance metrics, career timeline, or professional credentials. Despite a thorough search, no LinkedIn profile or reputable financial database entry was found for an Anna Lee in an analyst role at Truist. Accordingly, it is not possible to provide a professional profile consistent with the requested details.

Anna Lee's questions to CURIS (CRIS) leadership

Question · Q2 2025

Anna Lee from Truist inquired if recent FDA changes have impacted accelerated approval plans for PCNSL, asked for an update on business development efforts given the cash runway, and questioned broader oncology trends affecting Curis.

Answer

CDO Jonathan Zung stated that alignment with the FDA remains unchanged. CEO James Dentzer acknowledged industry-wide FDA uncertainty but felt confident due to PCNSL having no approved drugs. CFO Diantha Duvall confirmed the cash runway extends into 2026 and the company is actively evaluating financing opportunities.

Ask follow-up questions

Fintool

Fintool can predict CURIS logo CRIS's earnings beat/miss a week before the call